CN113116997B - Preparation method of storax pills - Google Patents
Preparation method of storax pills Download PDFInfo
- Publication number
- CN113116997B CN113116997B CN202110482971.4A CN202110482971A CN113116997B CN 113116997 B CN113116997 B CN 113116997B CN 202110482971 A CN202110482971 A CN 202110482971A CN 113116997 B CN113116997 B CN 113116997B
- Authority
- CN
- China
- Prior art keywords
- parts
- storax
- powder
- pill
- pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
- A61K36/835—Aquilaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
Abstract
The invention discloses a preparation method of storax pills. (1) mixing medicines: according to the prescription of the storax pill, except storax, artificial musk, borneol and buffalo horn concentrated powder, cinnabar is refined into fine powder by water; pulverizing the rest materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powder, grinding, sieving, and mixing to obtain mixed medicinal powder; stewing storax to obtain mixed medicinal powder; (2) preparation of the adhesive: putting glycerol into a container, adding medicinal carboxymethyl cellulose salt, stirring, sealing, and heating until carboxymethyl cellulose salt is completely swelled to obtain adhesive; (3) preparation of pills: adding adhesive 20-60% of the mixed powder into the mixed medicine, mixing, and making into pill. The storax pill prepared by the invention has the beneficial effects that refined honey and water are not used as adhesives, a drying process is not needed, the loss of volatile borneol and eugenol in a finished product is less, the content is relatively high, the dispersion time limit is low, and the quality is stable and controllable.
Description
Technical Field
The invention relates to storax pills, in particular to a preparation method of storax pills (soft pills).
Background
The storax pill mainly comprises storax, benzoinum, borneolum Syntheticum, pulvis Cornus Bubali Concentratus, artificial Moschus, lignum Santali albi, lignum Aquilariae Resinatum, flos Caryophylli, rhizoma Cyperi, radix aucklandiae, olibanum (preparata), fructus Piperis Longi, atractylodis rhizoma, fructus Chebulae and Cinnabaris, and is prepared by the following steps: refining Cinnabaris with water into fine powder except storax, artificial Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus; pulverizing the rest materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powders, grinding, sieving, and mixing. Stewing storax, adding appropriate amount of refined honey and water, making into water-honeyed pill, and drying at low temperature; or adding appropriate amount of refined honey to prepare into big honeyed pill, which has the following main functions: induce resuscitation with aromatics, move qi and alleviate pain. Can be used for treating phlegm syncope coma, apoplexy hemiplegia, limb disadvantageousness, heatstroke and heart and stomach qi pain caused by phlegm obstruction of heart orifice, and the standard is collected in the first part of 2020 edition of Chinese pharmacopoeia. The auxiliary materials added in the traditional storax pills are mainly honey, and the formed pills are usually dried in the preparation process. The prescription of the storax pill contains more volatile medicinal materials (decoction pieces), particularly clove and borneol, and after the storax pill is heated, the effective components of borneol and eugenol in the storax pill are lost, so that the medicine effect is influenced finally.
Disclosure of Invention
The invention aims to provide a preparation method of storax pills. The storax pill prepared by the invention has the characteristics of less loss of volatile borneol and eugenol in the finished product, relatively higher content, low dispersion time limit, stable and controllable quality without using refined honey and water as adhesives or drying process.
The technical scheme of the invention is as follows: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: weighing 50 parts of storax, 100 parts of benzoin, 50 parts of borneol, 200 parts of buffalo horn concentrated powder, 75 parts of artificial musk, 100 parts of sandalwood, 100 parts of agilawood, 100 parts of clove, 100 parts of rhizoma cyperi, 100 parts of elecampane, 100 parts of prepared frankincense, 100 parts of long pepper, 100 parts of bighead atractylodes rhizome, 100 parts of myrobalan meat and 100 parts of cinnabar according to the weight components, and refining cinnabar into fine powder by water except for the storax, the artificial musk, the borneol and the buffalo horn concentrated powder; pulverizing the rest materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powder, grinding, sieving, and mixing to obtain mixed medicinal powder; stewing storax to obtain a mixture, and mixing with the mixed medicinal powder to obtain a mixed medicine;
(2) Preparation of the adhesive: putting glycerol into a container, adding medicinal carboxymethyl cellulose salt, stirring, sealing, and heating until carboxymethyl cellulose salt is completely swelled to obtain adhesive;
(3) Preparation of the pill: adding 20-60% adhesive into the mixed medicinal materials, mixing, and making into pill.
In the aforementioned preparation method of storax pill, the pharmaceutically acceptable carboxymethyl cellulose salt comprises: sodium carboxymethyl cellulose or calcium carboxymethyl cellulose.
The preparation method of the storax pill comprises the following steps of (2) mixing glycerol and a pharmaceutically acceptable carboxymethyl cellulose salt = 100.
Specifically, in the step (2), the weight ratio of glycerin to pharmaceutically acceptable carboxymethyl cellulose salt = 100.
More specifically, the preparation method of the storax pill comprises the step (2) of mixing glycerol and a pharmaceutically acceptable carboxymethyl cellulose salt = 100.
In the step (2), the heating condition is that the Suhe incense pill is heated at 70-105 ℃ for 4-10 hours.
In the step (2), the heating is carried out once every 0.5-2 hours.
In the step (3) of the preparation method of the storax pills, the adhesive is added in a proportion of 25-50% of the amount of the mixed powder.
In the step (3) of the preparation method of the storax pills, the adhesive is added in a proportion of 30-45% of the amount of the mixed medicinal powder.
Compared with the prior art, the invention has the following beneficial effects:
the adhesive used in the invention meets the pharmacopeia standard, and has no toxic and side effects, and the prepared storax pill has the beneficial effects that refined honey and water are not used as adhesives, a drying process is not needed, the loss of volatile borneol and eugenol in a finished product is less, the content is relatively higher, the dispersion time limit is low, and the quality is stable and controllable.
The applicant applies the preparation technology of the soft pills to the gynecological reconstruction pills, the children rejuvenation pills, the six-ingredient rehmannia pills, the medlar-chrysanthemum rehmannia pills, the storax pills and the Zhibai-rehmannia pills, and obtains remarkable effects. The following is a test demonstration of storax-pliable pill. The inventors have performed a number of tests, some of which are reported below:
and (3) checking and recording the finished storax pill:
the purpose is as follows: volatile components of borneol and eugenol in the storax pills are easy to lose in the storage process, and the technology for well preserving the volatile substances is invented.
Prescription: 50g of storax, 100g of benzoin, 50g of borneol, 200g of buffalo horn concentrated powder, 75g of artificial musk, 100g of sandalwood, 100g of agilawood, 100g of clove, 100g of rhizoma cyperi, 100g of elecampane, 100g of frankincense (prepared), 100g of long pepper, 100g of bighead atractylodes rhizome, 100g of myrobalan meat and 100g of cinnabar.
The preparation method comprises the following steps: refining Cinnabaris with water into fine powder except storax, artificial Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus; pulverizing the rest materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powders, grinding, sieving, and mixing. And stewing the storax to obtain the final product.
Preparing a storax pill large honeyed pill (hereinafter referred to as a large honeyed pill): adding appropriate amount of refined honey, and making into big honeyed pill 960.
And (3) preparing Suhe fragrant pill water-honeyed pills (hereinafter referred to as water-honeyed pills): adding appropriate amount of refined honey and water, making into water-honeyed pill 960 pill, and drying at low temperature;
the invention relates to a preparation method of storax pills (hereinafter referred to as flexible pills):
preparing an adhesive: 97.00g of glycerin is weighed into a beaker, 4.03g of sodium carboxymethylcellulose is added, the mixture is stirred uniformly and heated for 7.1 hours at 90 ℃ for standby.
Mixing with 36.30-41.10% adhesive, and making into pill.
[ PROPERTIES ]
1. The product is ochre water-honeyed pill; fragrant smell, slightly bitter and pungent taste, as shown in figure 1.
2. The product is large honeyed pill with ochre color; fragrant smell, slightly bitter and pungent taste, as shown in fig. 2.
3. The product is soft pill with ochre color; fragrant smell, slightly bitter and pungent taste, as shown in fig. 3.
And (4) conclusion: the three types of pills are ochre pills with similar appearance.
Preparing a test sample;
preparing a water-honeyed pill test product: collecting 0.5400g of the product, cutting into pieces, adding 15ml of ethyl acetate, performing ultrasonic treatment for 2 min, filtering, concentrating the filtrate to near dryness, and adding 0.5ml of ethyl acetate to dissolve to obtain test solution.
Preparing a large honeyed pill test sample: collecting 0.5500g of the product, cutting into pieces, and making into the same preparation method as above water-honeyed pill.
Preparing a soft pill test sample: collecting 0.5401g of the product, cutting into pieces, and making into the same preparation as the above water-honeyed pill.
After being packaged in a commercially available package and placed for 1 month under the conditions of temperature of 40 +/-2 ℃ and relative humidity of 75% +/-5%, different pills are prepared and subjected to quality inspection.
[ IDENTIFICATION ]
1. Borneol (borneol)
Preparation of control: adding ethyl acetate into Borneolum Syntheticum control to obtain a solution containing 2.5mg of Borneolum Syntheticum control per 1ml, and making into control solution.
Temperature: 16 ℃, humidity: 65 percent;
scale model: ME204E, instrument number: HF-YF032;
name of reference substance: borneol, source: the Chinese food and drug testing institute;
batch number: 110743-201706, formulation batch number: 20201221;
developing agent: toluene-acetone (9: silica gel G;
sample amount of the test sample: 2 μ l, control spot size: 2 μ l.
Color development conditions are as follows: spraying 5% vanillin sulfuric acid solution, and heating until the color of the spot is clear. Spots of the same color appear on the chromatogram of the test solution at the positions corresponding to those on the chromatogram of the reference solution, as shown in FIG. 4, and Borneolum Syntheticum reference solution, soft pill, water-honeyed pill, and big honeyed pill are sequentially arranged from left to right in FIG. 4.
And (4) conclusion: the three pills can detect the components of the ice tablets, but the same sample application amount can find that the spots of the large honeyed pills are the lightest, the water honeyed pills are the second to the highest, and the soft pills are the thickest, and the analysis reason is that a large amount of honey exists in the large honeyed pills, the release of the components is blocked in the ultrasonic process, the components of the borneol are volatile, the drying process of the borneol in the water honeyed pills is reduced, the soft pills have no drying process, and the release of effective components is not influenced.
[ EXAMINATION ]
1. Moisture content: not more than 12.0%. (Water-honeyed pill)
Drying method
Temperature: 16 ℃, humidity: 66 percent;
scale model:
ME204E □MS205DU
balance number:
HF-YF032 □HF-YF033
the instrument model is as follows: 963360 GZX-9070MBE
GZX-9240MBE
Instrument numbering: 9633HF-YF 031
HF-YF015
Drying temperature: 105 ℃, drying time: 7 hours;
weigh flask (first, g) 77.6631; weighing bottle (constant weight, g) 77.6631;
sample amount (g): 3.1022;
weigh flask + sample (first, g) 80.4885; weigh flask + sample (second time, g) 80.4883;
weigh flask + sample (second, g) 80.4882.
And (3) calculating:
3.1022-(80.4882-77.6631)＝0.2771g
0.2771/3.1022*100％＝8.93％。
2. moisture content: not more than 15% (big honeyed pill)
Toluene process
Scale model:
ME204E □MS205DU
balance number:
HF-YF032 □HF-YF033
amount of toluene: 200ml;
moisture scale reading: 2.0ml;
sampling quantity: 14.62g;
and (3) calculating:
2.0/14.62g*100％＝13.67％
3. moisture content: must not exceed 9 percent (Soft pill)
Toluene process
Scale model:
ME204E □MS205DU
balance number:
HF-YF032 □HF-YF033
amount of toluene: 200ml;
moisture scale reading: 16.47g.
And (3) calculating:
1.3/16.47g*100％＝7.89％。
and (4) conclusion: the water content of the soft pill is still lower than that of large honeyed pills and water-honeyed pills under the condition of not being dried. 4. Dissolution time limit: complete dissolution should be achieved within 1 hour. (Water-honeyed pill)
Temperature: 6 ℃; humidity: 72 percent;
the appearance that disintegrates intelligently:
ZB-ID Instrument number:
HF-YF017
water temperature: 37.0 ℃; a disintegrating solvent: water;
complete disintegration time: and 56 minutes.
5. Dissolution time limit: complete dissolution should be achieved within 1 hour. (Soft pill)
Temperature: 6 ℃, humidity: 72 percent;
the intelligence appearance that disintegrates:
ZB-ID Instrument number:
HF-YF017
water temperature: 37.0 ℃, disintegration solvent: water;
complete disintegration time: for 47 minutes.
And (4) conclusion: the disintegration time of the soft pills is not greatly different from that of the water-honeyed pills, can completely meet the requirements, and does not influence the absorption effect.
Content determination:
the measurement was carried out by gas chromatography (0521 in 2015 th edition of the general rules of the four departments).
Temperature: 25 ℃, humidity: 66 percent;
scale model: ME204E; balance number: HF-YF032;
the instrument model is as follows: GC-2014C gas chromatograph, number: HF-YF050;
capillary column: specification: polyethylene glycol capillary column;
name of reference substance: borneol and eugenol reference substance, the sources are as follows: the Chinese food and drug testing institute;
borneol reference lot No.: 110881 to 201709, control solution preparation batch number: 20210129;
eugenol reference lot number: 110725 to 201917, and the preparation batch number of the control solution: 20210129;
column temperature: 250 ℃, detector temperature: 70 ℃;
chromatographic conditions and system applicability test: polymerization-crosslinking polyethylene glycol 20000 (PEG-20M) capillary chromatographic column (column length of 30M, inner diameter of 0.25mm, membrane thickness of 0.25 μ M); the column temperature was programmed at an initial temperature of 115 ℃ for 8 minutes, then increased to 180 ℃ at a rate of 120 ℃ per minute for 10 minutes, and then increased to 250 ℃ at a rate of 120 ℃ per minute for 5 minutes. The number of theoretical plates is not less than 40000 calculated according to borneol peak.
Preparation of control solutions: weighing appropriate amount of Borneolum Syntheticum reference substance and eugenol reference substance, precisely weighing, and adding ethyl acetate to obtain solution containing 0.3mg Borneolum Syntheticum per 1ml and solution containing 0.1mg eugenol per 1 ml.
Preparation of a test solution: taking 10 pills of the product, precisely weighing, grinding water-honeyed pills, shearing large honeyed pills, taking 4g of the product, precisely weighing, precisely adding 2-4 g of diatomite, grinding, precisely weighing a proper amount (which is about equal to the amount of a half pill), precisely weighing, precisely adding 20ml of ethyl acetate, weighing, carrying out ultrasonic treatment (with the power of 300W and the frequency of 50 kHz) for 30 minutes, cooling, weighing again, complementing the lost weight with ethyl acetate, shaking uniformly, filtering, and taking the subsequent filtrate to obtain the traditional Chinese medicine.
The determination method comprises the following steps: precisely sucking 1 μ l of each of the reference solution and the sample solution, injecting into gas chromatograph, and measuring.
Each pill of the product contains Borneolum Syntheticum and Borneolum Syntheticum (C) 10 H 18 O), the water-honeyed pill is not less than 14.0mg, and the big honeyed pill is not less than 10.0mg; containing eugenol (C) and flos Caryophylli 10 H 12 O 2 ) The water-honeyed pill should not be less than 5.0mg, and the big honeyed pill should not be less than 3.5mg.
Weighing borneol: 0.10560g, concentration: 0.10518mg/ml;
weighing eugenol: 4.0ml, concentration: 0.07928ml/ml;
average peak area of control
(borneol): 630943.5;
average peak area of control
(eugenol): 50532893.5;
dilution multiple: 20;
weighing the water-honeyed pill: 4.0902g;
peak area (1) of the test sample of the water-honeyed pill (borneol): 21066383;
peak area (2) of the test sample of the water-honeyed pill (borneol): 20743217;
average peak area of test sample of water-honeyed pill (borneol): 20904800;
peak area of test sample of water-honeyed pill (eugenol): 8293127;
peak area of test sample of water-honeyed pill (eugenol): 8293127;
average peak area of water-honeyed pill (eugenol): 8212475.5;
weighing large honeyed pills: 4.0765;
peak area of large honeyed pill (borneol): 20317507;
peak area of large honeyed pill (eugenol): 4919880.
weighing the flexible pill sample (1): 4.0392g; weighing the flexible pill sample (2): 4.2030g;
peak area (1) (borneol) of soft pill sample (1): 44783491;
peak area (2) (borneol) of soft pill sample (1): 45277505;
average peak area (borneol) of the soft pill test sample (1): 45030498;
peak area (1) (borneol) of soft pill sample (2): 46953400;
peak area (2) (borneol) of the soft pill sample (2): 46953400;
average peak area (borneol) of the soft pill sample (2): 46805262;
peak area (1) of flexible pill sample (1) (eugenol): 10028128;
peak area (2) (eugenol) of flexible pill sample (1): 10054041;
average peak area (eugenol) of flexible pill test sample (1): 10041084.5;
peak area (1) of flexible pill sample (2) (eugenol): 10065611;
peak area (2) (eugenol) of the soft pill sample (2): 9965317;
average peak area (eugenol) of the soft pill sample (2): 10015464;
note: (chromatograms are shown in FIGS. 5-15);
and (3) calculating:
calculating the borneol content in each pill:
water-honeyed pills:
big honeyed pill:
flexible pill 1:
and (2) flexible pill:
calculating the content of eugenol in each pill:
water-honeyed pills:
big honeyed pill:
flexible pill 1:
flexible pill 2:
and (4) conclusion: the determination of the contents of the pellets prepared by the three processes after 1 month acceleration found that: for borneol with stronger volatility, the soft pill process of the invention embodies more obvious effect, has obvious difference, adopts innovative process to have obvious effect on the component retention of the borneol, and has better effect on the volatilization of eugenol compared with large honeyed pills.
In conclusion, the storax pill prepared by the invention has the beneficial effects that refined honey and water are not used as adhesives, a drying process is not needed, the loss of volatile borneol and eugenol in a finished product is less, the content is relatively high, the dispersion time limit is low, and the quality is stable and controllable.
Drawings
FIG. 1 is a diagram of a water-honeyed pill in the form of a substance for testing and proving the properties of the invention;
FIG. 2 is a diagram of a large honeyed pill in the middle of the property proved by the experiment of the present invention;
FIG. 3 is a pictorial representation of a soft pellet (storax pellet of the present invention) in the experimental demonstration-trait of the present invention;
FIG. 4 is a thin-layer diagram of the present invention for identification of borneol;
FIG. 5 is a chromatogram of a control borneol in the assay of the invention;
FIG. 6 is a chromatogram of a control borneol in the assay of the invention;
FIG. 7 is a chromatogram of a reference eugenol in the assay proof-content determination of the invention;
FIG. 8 is a chromatogram of a reference eugenol in the assay proof-content determination of the invention;
FIG. 9 is a chromatogram of a test sample of water-honeyed pill for assay proof of the present invention;
FIG. 10 is a chromatogram of a water-honeyed pill test sample for assay proof of the present invention;
FIG. 11 is a chromatogram of a large honeyed pill test sample in the assay of the invention;
FIG. 12 is a chromatogram of a soft pellet sample (1) in the assay demonstration-content determination of the present invention;
FIG. 13 is a chromatogram of a soft pellet sample (1) in the assay proof-content determination of the present invention;
FIG. 14 is a chromatogram of the soft pellet sample (2) in the assay demonstration-content determination of the present invention;
FIG. 15 is a chromatogram of the soft pellet sample (2) in the assay proof-content determination of the present invention.
Detailed Description
The invention is further illustrated by the following figures and examples, which are not to be construed as limiting the invention.
Example 1: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: weighing 50g of storax, 100g of benzoin, 50g of borneol, 200g of buffalo horn concentrated powder, 75g of artificial musk, 100g of sandalwood, 100g of agilawood, 100g of clove, 100g of rhizoma cyperi, 100g of elecampane, 100g of prepared frankincense, 100g of long pepper, 100g of bighead atractylodes rhizome, 100g of myrobalan meat and 100g of cinnabar according to the weight components, and refining cinnabar into fine powder by water except the storax, the artificial musk, the borneol and the buffalo horn concentrated powder; pulverizing the rest materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powder, grinding, sieving, and mixing to obtain mixed medicinal powder; stewing storax to obtain mixed medicinal powder;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 4.15g of sodium carboxymethylcellulose, stirring uniformly, sealing, heating at 90 ℃ for 7 hours until the sodium carboxymethylcellulose is completely swelled, and stirring once every 1 hour to prepare an adhesive for later use;
(3) Preparation of pills: adding adhesive in an amount which is 38 percent of the mixed medicinal powder into the medicinal powder, uniformly mixing, and making pills.
Example 2: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of example one;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 2g of sodium carboxymethylcellulose, stirring uniformly, sealing, heating at 70 ℃ for 10 hours until the sodium carboxymethylcellulose is completely swelled, and stirring once every 1 hour to prepare an adhesive for later use;
(3) Preparation of pills: adding adhesive in an amount which is 30 percent of the mixed medicinal powder into the medicinal powder, uniformly mixing, and making into pills.
Example 3: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of the first embodiment;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 6g of carboxymethylcellulose calcium, stirring uniformly, sealing, heating at 80 ℃ for 8 hours until the carboxymethylcellulose calcium is completely swelled, and stirring once every 1.5 hours to obtain an adhesive for later use;
(3) Preparation of pills: adding adhesive in 45% of the powder, mixing, and making into pill.
Example 4: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of the first embodiment;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 8g of carboxymethylcellulose calcium, stirring uniformly, sealing, heating at 90 ℃ for 7 hours until the carboxymethylcellulose calcium is completely swelled, and stirring once every 1.5 hours to prepare an adhesive for later use;
(3) Preparation of the pill: adding adhesive in an amount which is 40 percent of the mixed medicinal powder into the medicinal powder, uniformly mixing, and making pills.
Example 5: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of example one;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 10g of sodium carboxymethylcellulose, stirring uniformly, sealing, heating at 100 ℃ for 5 hours until the sodium carboxymethylcellulose is completely swelled, and stirring once every 2 hours to obtain an adhesive for later use;
(3) Preparation of the pill: adding adhesive in an amount which is 25 percent of the amount of the mixed medicinal powder into the medicinal powder, uniformly mixing, and making pills.
Example 6: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of the first embodiment;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 15g of sodium carboxymethylcellulose, stirring uniformly, sealing, heating at 95 ℃ for 6 hours until the sodium carboxymethylcellulose is completely swelled, and stirring once every 0.5 hour to obtain an adhesive for later use;
(3) Preparation of pills: adding adhesive in an amount of 50% of the mixed powder into the medicinal powder, mixing uniformly, and making into pill.
Example 7: a preparation method of storax pills comprises the following steps:
(1) Mixing the medicines: prepared according to the method of example one;
(2) Preparation of the adhesive: adding 100g of glycerol into a container, adding 1g of carboxymethylcellulose calcium, stirring uniformly, sealing, heating at 90 ℃ for 7 hours until the carboxymethylcellulose calcium is completely swelled, and stirring once every 1 hour to prepare an adhesive for later use;
(3) Preparation of the pill: adding adhesive in 45% of the powder, mixing, and making into pill.
Claims (1)
1. A preparation method of storax pills is characterized by comprising the following steps: the method comprises the following steps:
(1) Mixing the medicines: weighing 50 parts of storax, 100 parts of benzoin, 50 parts of borneol, 200 parts of buffalo horn concentrated powder, 75 parts of artificial musk, 100 parts of sandalwood, 100 parts of agilawood, 100 parts of clove, 100 parts of rhizoma cyperi, 100 parts of elecampane, 100 parts of prepared frankincense, 100 parts of long pepper, 100 parts of bighead atractylodes rhizome, 100 parts of myrobalan meat and 100 parts of cinnabar according to the weight components, and refining cinnabar into fine powder by water except the storax, the artificial musk, the borneol and the buffalo horn concentrated powder; pulverizing the rest ten materials into fine powder; respectively grinding Moschus, borneolum Syntheticum, and pulvis Cornus Bubali Concentratus into fine powder, mixing with above powder, grinding, sieving, and mixing to obtain mixed medicinal powder; stewing storax to obtain mixed medicinal powder;
(2) Preparation of the adhesive: weighing 97.00g of glycerin, putting the glycerin into a beaker, adding 4.03g of sodium carboxymethylcellulose, uniformly stirring, and heating for 7.1 hours at 90 ℃ for later use;
(3) Preparation of pills: adding binder in the proportion of 36.30-41.10% of mixed powder into the mixed medicine, mixing uniformly, and making into pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110482971.4A CN113116997B (en) | 2021-04-30 | 2021-04-30 | Preparation method of storax pills |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110482971.4A CN113116997B (en) | 2021-04-30 | 2021-04-30 | Preparation method of storax pills |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113116997A CN113116997A (en) | 2021-07-16 |
| CN113116997B true CN113116997B (en) | 2022-10-21 |
Family
ID=76780720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110482971.4A Active CN113116997B (en) | 2021-04-30 | 2021-04-30 | Preparation method of storax pills |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113116997B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363331A (en) * | 2001-01-09 | 2002-08-14 | 杨孟君 | Nano storax medicine and its preparing process |
| CN1660332A (en) * | 2004-12-22 | 2005-08-31 | 康国忠 | Drop pills preparation of dual goldthread root and preparation method |
| CN101229306A (en) * | 2008-02-27 | 2008-07-30 | 北京金方华医药科技有限公司 | Guyinjian oral preparation and preparing method thereof |
| CN106110143A (en) * | 2016-07-14 | 2016-11-16 | 贵州汉方药业有限公司 | A kind of processing technology of Zaizao preparation |
| CN106120295A (en) * | 2016-08-16 | 2016-11-16 | 朱玲 | A kind of glycerol sodium carboxymethyl cellulose Compositional type hydrogen peroxide bleaching stabilizer and application thereof |
| CN111228322A (en) * | 2019-12-30 | 2020-06-05 | 贵州汉方药业有限公司 | Preparation method of heat-clearing and stagnation-eliminating tablet |
-
2021
- 2021-04-30 CN CN202110482971.4A patent/CN113116997B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1363331A (en) * | 2001-01-09 | 2002-08-14 | 杨孟君 | Nano storax medicine and its preparing process |
| CN1660332A (en) * | 2004-12-22 | 2005-08-31 | 康国忠 | Drop pills preparation of dual goldthread root and preparation method |
| CN101229306A (en) * | 2008-02-27 | 2008-07-30 | 北京金方华医药科技有限公司 | Guyinjian oral preparation and preparing method thereof |
| CN106110143A (en) * | 2016-07-14 | 2016-11-16 | 贵州汉方药业有限公司 | A kind of processing technology of Zaizao preparation |
| CN106120295A (en) * | 2016-08-16 | 2016-11-16 | 朱玲 | A kind of glycerol sodium carboxymethyl cellulose Compositional type hydrogen peroxide bleaching stabilizer and application thereof |
| CN111228322A (en) * | 2019-12-30 | 2020-06-05 | 贵州汉方药业有限公司 | Preparation method of heat-clearing and stagnation-eliminating tablet |
Non-Patent Citations (1)
| Title |
|---|
| 戊己丸的现代研究进展;张建锋,等;《中医学报》;20170131;第32卷(第01期);第96-98页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113116997A (en) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2307558A1 (en) | Effervescent granules | |
| Sayyad et al. | Preparation and evaluation of fermented Ayurvedic formulation: Arjunarishta | |
| CN104042824B (en) | Preparation and detecting methods of traditional Chinese medicine composition for treating wind-cold-wetness evil | |
| MX2012009688A (en) | Capsule of complex danshen drop pill. | |
| WO2005053658A1 (en) | Butylphthalide soft gel capsule and its preparatin procedure | |
| CN102614281B (en) | Chinese medicinal composition for improving anoxia endurance and preparation method and application thereof | |
| CN113116997B (en) | Preparation method of storax pills | |
| AU2020104149A4 (en) | Ginseng-antler energy peptide having an anti-aging effect, microcapsule, and preparation method and use thereof | |
| CN1733266A (en) | Chinese traditional medicine preparation for relieving food retention, resolving stagnation and harmonizing stomach, process for preparing the same and quality controlling method thereof | |
| CN101278976B (en) | Quality control method of Shangke bone-knitting medicine | |
| CN107184661A (en) | The direct oral traditional Chinese medicine medicine materical crude slice of vinegar tetrahydropalmatine | |
| CN100506207C (en) | Compound salvia miltiorrhiza delayed-release preparation and preparation method thereof | |
| Brown et al. | Determination of Phenolic Constituents in Echinacea Raw Materials and Dietary Supplements by HPLC–UV: Collaborative Study | |
| CN100500195C (en) | Medicinal Smilax indica micro pill and its preparing method | |
| CN113117008B (en) | Preparation method of Zhibai Dihuang pills | |
| CN102133368B (en) | Quality detection method for intestines and stomach easing capsule | |
| CN117224588B (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN113041311A (en) | Preparation method of pill of six ingredients with rehmannia | |
| CN1239905C (en) | Method for control quality of Chinese medicinal preparation | |
| CN113197959A (en) | Preparation method of pill containing wolfberry, chrysanthemum and rehmannia | |
| CN113633733B (en) | Preparation method of gynecological reconstruction pill | |
| CN112903895A (en) | Mongolian medicinal material elecampane inula root formula powder quality standard and detection method | |
| CN112569281B (en) | Yiqing composition and preparation method thereof | |
| Patil et al. | A comparative study of physico-chemical analysis of Ashwagandha Ghrita and Sapta Avarthita Ashwagandha Ghrita | |
| CN102188468A (en) | Preparation method of Xinnaoshutong tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230830 Address after: No.8, Zone A, Zhazuo Pharmaceutical Park, Xiuwen County, Guiyang City, Guizhou Province, 550200 Patentee after: Guizhou Dechangxiang Pharmaceutical Co.,Ltd. Address before: No.118 Chuangwei Road, Baiyun District, Guiyang City, Guizhou Province Patentee before: HANFANG PHARMA CO.,LTD. Patentee before: Guiyang Dechangxiang Pharmaceutical Co.,Ltd. |